Type 2 Diabetes or Obesity/Overweight Comorbidities
Conditions
Interventions
Experimental Group:Basic treatment+Transcutaneous Auricular Electrical Stimulation
Control Group:Basic treatment+Non-Auricular Electrical Stimulation on External Ear
Sponsors
Guang'anmen Hospital of the Chinese Academy of Traditional Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Meet diagnostic criteria for type 2 diabetes, obesity, or overweight comorbidities: Type 2 diabetes patients must have fasting blood glucose =126 mg/dL (7.0 mmol/L), HbA1c =6.5%, or 2-hour postprandial blood glucose =200 mg/dL (11.1 mmol/L); obesity patients must have BMI =30 kg/m²; overweight patients with comorbidities must have BMI =27 kg/m² and at least one complication such as hypertension or dyslipidemia. 2. Age 18-70 years. 3. Experience gastrointestinal symptoms (e.g., nausea, vomiting) after semaglutide injection with RINVR score =20 and =32. 4. Voluntarily participate and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Participants with severe cardiovascular, cerebrovascular, hepatic, hematopoietic system diseases, or other life-threatening conditions. 2. Participants with hepatic/renal insufficiency or cirrhosis. 3. Participants with fever or infectious diseases. 4. Pregnant or lactating women. 5. Participants with psychiatric disorders or inability to cooperate with treatment. 6. Participants with cardiac pacemakers or allergies to trial interventions. 7. Participants using prokinetic drugs or medications alleviating gastrointestinal side effects (e.g., ondansetron, metoclopramide, dexamethasone). 8. Participants with gastrointestinal disorders causing nausea/vomiting (e.g., diabetic gastroparesis). 9. Participants with acute pancreatitis, diabetic retinopathy, or thyroid diseases. 10. Participants with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) within 6 months, or fasting blood glucose =13.9 mmol/L (250 mg/dL), HbA1c =10%, or random blood glucose =16.7 mmol/L (300 mg/dL). 11. Participation in other clinical trials within 3 months with potential interference.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rhodes Index of Nausea, Vomiting, and Retching(RINVR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Simplified Nutritional Appetite Questionnaire (SNAQ);Visual Analog Scale(VAS);Serological Indicators;Anthropometric Indicators;Gastrointestinal Symptom Rating Scale; | — |
Countries
China
Contacts
Public ContactWenke Liu
Guang'anmen Hospital of the Chinese Academy of Traditional Medicine
Outcome results
None listed